Adjuvant systemic therapy for breast cancer. Issues for primary care physicians

Area of Science:

• Oncology
• Breast Cancer Management

Background:

• Adjuvant therapy (chemotherapy, hormone therapy) is crucial for managing breast cancer.
• Early systemic treatment can prevent micrometastatic disease progression.
• Positive axillary nodes are a primary risk factor for systemic recurrence.

Purpose of the Study:

• To evaluate the indications for adjuvant therapy in breast cancer.
• To determine the role of tumor size and lymph node status in treatment decisions.
• To assess the value of intensive follow-up protocols.

Main Methods:

• Review of current clinical practices and risk factors in breast cancer adjuvant therapy.
• Analysis of tumor size and axillary node status in relation to prognosis.
• Evaluation of the benefits and costs of scheduled follow-up testing.

Main Results:

• Adjuvant therapy is generally advised for patients with positive axillary nodes.
• Tumor size is critical for patients with negative nodes: therapy may be avoided for lesions <1 cm but is advisable for those >2 cm.
• Intense follow-up does not consistently improve survival and can be costly.

Conclusions:

• Adjuvant therapy decisions should be guided by lymph node status and tumor size.
• Less routine testing may be appropriate for asymptomatic breast cancer patients.
• Optimizing follow-up strategies can enhance cost-effectiveness without compromising patient outcomes.